|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
<b>Background</b>: This updated meta-analysis aimed to analyze available data to explore the prognostic value of long noncoding RNA breast cancer anti-estrogen resistance 4 (BCAR4) in various human malignancies.
|
31762809 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<b>Conclusions</b>: High expression of BCAR4 was correlated with unfavorable overall survival outcome and clinical features including metastasis and progression, implicating an independent prognostic value for BCAR4 in human cancers.
|
31762809 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Breast cancer antiestrogen resistance 4 (BCAR4) was identified in a functional screen for genes involved in tamoxifen resistance.
|
21506106 |
2011 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Breast cancer antiestrogen resistance 4 (BCAR4) was identified in a functional screen for genes involved in tamoxifen resistance.
|
21506106 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor xenograft was conducted to determine the effects of BCAR4 and <i>GLI2</i> on NSCLC tumorigenesis in vivo.
|
29615150 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Breast cancer antiestrogen resistance 4 (BCAR4) is a novel long noncoding RNA.
|
30537165 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Breast cancer antiestrogen resistance 4 (BCAR4) is a novel long noncoding RNA.
|
30537165 |
2019 |
|
Mammary Neoplasms
|
0.330 |
Biomarker
|
group |
CTD_human |
BCAR4 mRNA levels were measured in primary breast tumours, and evaluated for association with progression-free survival (PFS) and clinical benefit in patients with oestrogen receptor (ERα)-positive tumours receiving tamoxifen as first-line monotherapy for advanced disease.
|
20859285 |
2010 |
|
Mammary Neoplasms
|
0.330 |
AlteredExpression
|
group |
BEFREE |
BCAR4 mRNA levels were measured in primary breast tumours, and evaluated for association with progression-free survival (PFS) and clinical benefit in patients with oestrogen receptor (ERα)-positive tumours receiving tamoxifen as first-line monotherapy for advanced disease.
|
20859285 |
2010 |
|
Mammary Neoplasms
|
0.330 |
AlteredExpression
|
group |
BEFREE |
BCAR4 is expressed in 27% of primary breast tumors.
|
21506106 |
2011 |
|
Mammary Neoplasms
|
0.330 |
Biomarker
|
group |
CTD_human |
BCAR4 is expressed in 27% of primary breast tumors.
|
21506106 |
2011 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BCAR4 expression strongly sensitised ZR-75-1 and MCF7 breast cancer cells to the combination of lapatinib and antioestrogens.
|
22892392 |
2012 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
BCAR4 expression correlates with advanced breast cancers, and therapeutic delivery of locked nucleic acids (LNAs) targeting BCAR4 strongly suppresses breast cancer metastasis in mouse models.
|
25416949 |
2014 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
BCAR4 expression correlates with advanced breast cancers, and therapeutic delivery of locked nucleic acids (LNAs) targeting BCAR4 strongly suppresses breast cancer metastasis in mouse models.
|
25416949 |
2014 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
BCAR4 expression correlates with advanced breast cancers, and therapeutic delivery of locked nucleic acids (LNAs) targeting BCAR4 strongly suppresses breast cancer metastasis in mouse models.
|
25416949 |
2014 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BCAR4 mRNA expression was evaluated by (q)RT-PCR in a panel of human normal tissues, primary breast cancers and cell lines.
|
26317614 |
2015 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
BCAR4 promotes the invasion and metastasis of NSCLC via regulating EMT and BCAR4/EMT interaction can be used as a new target for the diagnosis and therapeutics of NSCLC.
|
28537678 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BCAR4 is reported to be highly expressed in breast cancer and promotes cell proliferation.
|
28537678 |
2017 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BCAR4 is reported to be highly expressed in breast cancer and promotes cell proliferation.
|
28537678 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
BCAR4 was higher in NSCLC tissues than that in cancer-adjacent tissues and was positively correlated with tumor size, clinical stage, and distant metastasis, suggesting that BCAR4 can be used as an independent predictor of prognosis.
|
28537678 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BCAR4 was higher in NSCLC tissues than that in cancer-adjacent tissues and was positively correlated with tumor size, clinical stage, and distant metastasis, suggesting that BCAR4 can be used as an independent predictor of prognosis.
|
28537678 |
2017 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
BCAR4 was higher in NSCLC tissues than that in cancer-adjacent tissues and was positively correlated with tumor size, clinical stage, and distant metastasis, suggesting that BCAR4 can be used as an independent predictor of prognosis.
|
28537678 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
BCAR4 (Breast Cancer Anti-Estrogen Resistance 4) is a long noncoding RNA that was identified as an oncogene in breast cancer.
|
29190958 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
BCAR4 (Breast Cancer Anti-Estrogen Resistance 4) is a long noncoding RNA that was identified as an oncogene in breast cancer.
|
29190958 |
2017 |
|
Malignant tumor of colon
|
0.020 |
Biomarker
|
disease |
BEFREE |
BCAR4 may be a useful new target for treatment of patients with colon cancer.
|
29190958 |
2017 |